Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

March 15, 2021March 15, 2021

Takeda Seeks Approval in Japan of Takhzyro to Prevent Swelling Attacks

News

Takeda has submitted an application in Japan seeking regulatory approval of Takhzyro (lanadelumab) for the treatment of hereditary angioedema (HAE). The company’s new drug application to the Japanese Ministry of ... Read more

March 5, 2021March 5, 2021

Long-term Haegarda Found to Improve Quality of Life in HAE Patients

News

Long-term treatment with the approved therapy Haegarda leads to improved quality of life in people with type 1 or 2 hereditary angioedema (HAE), new clinical trial data show. The findings ... Read more

February 19, 2021February 19, 2021

HAE Patients in US Favored Oral Prophylactic in 2018 Survey

News

People with hereditary angioedema (HAE) would prefer an oral medication that could prevent their attacks, even when satisfied with their current treatment, a survey of patients in the U.S. reports. ... Read more

January 25, 2021January 25, 2021

Orladeyo Approved in Japan to Prevent Swelling Attacks Due to HAE

News

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved oral Orladeyo (berotralstat), at a daily dose of 150 mg, to prevent hereditary angioedema (HAE) attacks in individuals ages 12 and up. ... Read more

January 22, 2021January 22, 2021

Rare Genetic Variations in KNG1, XPNPEP1 Linked to HAE With Normal C1-INH

News

Variations in the genes KNG1 and XPNPEP1 may be associated with hereditary angioedema (HAE) that occurs in people without any of the mutations that typically cause the disease, a new study suggests. ... Read more

January 18, 2021January 18, 2021

Better Quality of Life Evident in HAE Patients Using Takhzyro in Pivotal Trial

News

Treatment with Takhzyro (lanadelumab) significantly improves health-related quality of life in people with hereditary angioedema (HAE), new data from its pivotal clinical trial show. While all dose regimens improved patient ... Read more

January 4, 2021January 4, 2021

3 Methods for Measuring C1-INH Activity Give Comparable Results

News

Assessing C1-inhibitor (C1-INH) activity for the diagnosis and monitoring of hereditary angioedema (HAE) can be done through three distinct validated methods with similar accuracy, a new study found. The study, ... Read more

November 6, 2020November 6, 2020

Berotralstat Significantly Lowers HAE Attack Frequency, Phase 3 Trial Reports

News

Preventive treatment with oral berotralstat (BCX7353) significantly lowers the frequency of swelling attacks in people with hereditary angioedema (HAE), newly published results from the APeX-2 clinical trial demonstrate. The study, “Oral once-daily ... Read more

November 2, 2020November 2, 2020

NORD Hosting ‘RareLaunch’ Workshops to Help Start Rare Disease Non-profits

News, syndicated

The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops in December, with the aim of empowering leaders to start non-profit organizations ... Read more

October 30, 2020October 30, 2020

HAE Attack in Fetus Reported, Baby Responded to Mom’s Treatment

News

The first documented case of a hereditary angioedema (HAE) attack in an unborn child — whose symptoms resolved after treating the mother with the recombinant human C1-inhibitor (rhC1-INH) therapy, Ruconest — has ... Read more